Mizuho Securities Keeps Their Buy Rating on Selecta Biosciences (SELB)


In a report released today, Difei Yang from Mizuho Securities maintained a Buy rating on Selecta Biosciences (SELB), with a price target of $30. The company’s shares closed on Friday at $5.65, close to its 52-week low of $4.74.

Yang said:

“We hosted a doc call on 10/29 to discuss SEL-212. Our consultant noted some of the main potential advantages of SEL-212 vs. the standard of care including; 1) Improved treatment regimen with fewer infusions (1x/month) vs. a proposed Krystexxa combo (2x/month + daily or weekly anti-proliferative agent) and 2) Superior safety profile. Our consultant believes SEL-212 is ready for phase 3 given considerable amounts of data generated to date on treatment regimen and dosing along with clear objective measurements showing tophi mitigation and lowering of uric acid levels in a majority of patients. She argued that had the stopping rules not been as stringent in the phase 2 trial, the results may have looked better.”

According to TipRanks.com, Yang is a 5-star analyst with an average return of 19.4% and a 48.5% success rate. Yang covers the Healthcare sector, focusing on stocks such as Alder Biopharmaceuticals, Audentes Therapeutics, and Revance Therapeutics.

Currently, the analyst consensus on Selecta Biosciences is a Strong Buy with an average price target of $35, a 519.5% upside from current levels. In a report issued on October 23, Janney Montgomery also maintained a Buy rating on the stock.

.

See today’s analyst top recommended stocks >>

Based on Selecta Biosciences’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $18.8 million. In comparison, last year the company had a GAAP net loss of $14.68 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The firm produces the Synthetic Vaccine Particles (SVP) platform for immune tolerance and immune stimulation.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts